Cita APA (7a ed.)

Peng, Y., Zeng, X., Peng, L., Liu, Q., Yi, L., Luo, X., . . . Tan, C. (2021). Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy. Frontiers Media S.A.

Cita Chicago Style (17a ed.)

Peng, Ye, et al. Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy. Frontiers Media S.A, 2021.

Cita MLA (8a ed.)

Peng, Ye, et al. Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy. Frontiers Media S.A, 2021.